Oxford vaccine candidate is already in large-scale Phase III human trials in Brazil to assess whether it can protect against COVID-19, but its developers have yet to report Phase I results."We expect this paper, which is undergoing final editing and preparation, to be published on Monday, July 20, for immediate release," Reuters quoted a spokeswoman for the journal as saying.The Lancet's statement came after reports said that the Phase I data could be released as soon Thursday.Developers of the Oxford vaccine, known as known as AZD1222, said earlier this month they were encouraged by the immune response they had seen in trials so far and were expecting to publish Phase 1 data by the end of July.More than 100 vaccines are being developed and.